1. Home
  2. LXRX vs AMBI Comparison

LXRX vs AMBI Comparison

Compare LXRX & AMBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LXRX
  • AMBI
  • Stock Information
  • Founded
  • LXRX 1995
  • AMBI 1995
  • Country
  • LXRX United States
  • AMBI Brazil
  • Employees
  • LXRX N/A
  • AMBI N/A
  • Industry
  • LXRX Biotechnology: Pharmaceutical Preparations
  • AMBI Environmental Services
  • Sector
  • LXRX Health Care
  • AMBI Industrials
  • Exchange
  • LXRX Nasdaq
  • AMBI Nasdaq
  • Market Cap
  • LXRX 352.5M
  • AMBI 290.4M
  • IPO Year
  • LXRX 2000
  • AMBI N/A
  • Fundamental
  • Price
  • LXRX $0.75
  • AMBI $5.60
  • Analyst Decision
  • LXRX Buy
  • AMBI
  • Analyst Count
  • LXRX 2
  • AMBI 0
  • Target Price
  • LXRX $6.00
  • AMBI N/A
  • AVG Volume (30 Days)
  • LXRX 4.9M
  • AMBI 8.4K
  • Earning Date
  • LXRX 11-12-2024
  • AMBI 01-01-0001
  • Dividend Yield
  • LXRX N/A
  • AMBI N/A
  • EPS Growth
  • LXRX N/A
  • AMBI 3161.09
  • EPS
  • LXRX N/A
  • AMBI 0.56
  • Revenue
  • LXRX $5,229,000.00
  • AMBI $504,573,816.00
  • Revenue This Year
  • LXRX $886.38
  • AMBI N/A
  • Revenue Next Year
  • LXRX $181.58
  • AMBI N/A
  • P/E Ratio
  • LXRX N/A
  • AMBI $10.61
  • Revenue Growth
  • LXRX 886.60
  • AMBI 25.13
  • 52 Week Low
  • LXRX $0.62
  • AMBI $3.07
  • 52 Week High
  • LXRX $3.73
  • AMBI $8.44
  • Technical
  • Relative Strength Index (RSI)
  • LXRX 38.05
  • AMBI 51.64
  • Support Level
  • LXRX $0.72
  • AMBI $5.20
  • Resistance Level
  • LXRX $0.85
  • AMBI $5.93
  • Average True Range (ATR)
  • LXRX 0.09
  • AMBI 0.58
  • MACD
  • LXRX 0.03
  • AMBI 0.09
  • Stochastic Oscillator
  • LXRX 33.10
  • AMBI 77.70

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

About AMBI Ambipar Emergency Response

Ambipar Emergency Response is a environmental, emergency response and industrial field service provider in Brazil with presence in 16 countries in Latin America, North America, Europe, Africa and Antarctica. The company provides customers with a full suite of environmental services organized around prevention, training and emergency response on all transportation modes. The portfolio includes a broad variety of services such as environmental remediation, industrial field services, industrial cleaning of chemical and non-chemical products and of hazardous and non-hazardous waste, consulting services focused on accident prevention and environmental licensing.

Share on Social Networks: